301015 百洋医药
已收盘 05-12 15:00:00
资讯
新帖
简况
百洋医药：公司持续丰富运营产品矩阵
证券之星 · 04-30
百洋医药：公司持续丰富运营产品矩阵
百洋医药（301015）2026年一季报简析：净利润同比增长45.79%，盈利能力上升
证券之星 · 04-30
百洋医药（301015）2026年一季报简析：净利润同比增长45.79%，盈利能力上升
4月29日百洋医药涨5.01%，益民创新优势混合A基金重仓该股
证券之星 · 04-29
4月29日百洋医药涨5.01%，益民创新优势混合A基金重仓该股
上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参
每日经济新闻 · 04-29
上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参
图解百洋医药年报：第四季度单季净利润同比下降103.45%
证券之星 · 04-29
图解百洋医药年报：第四季度单季净利润同比下降103.45%
百洋医药：公司运营品牌安博美的销售按经营计划有序开展
证券之星 · 04-27
百洋医药：公司运营品牌安博美的销售按经营计划有序开展
百洋医药：ZAP-X已完成在北京大学国际医院、北京天坛普华医院的落地部署
证券之星 · 04-27
百洋医药：ZAP-X已完成在北京大学国际医院、北京天坛普华医院的落地部署
百洋医药：公司目前无自建核药药房的经营计划
证券之星 · 04-27
百洋医药：公司目前无自建核药药房的经营计划
百洋医药：核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营
证券之星 · 04-20
百洋医药：核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营
股市必读：百洋医药（301015）4月17日董秘有最新回复
证券之星 · 04-20
股市必读：百洋医药（301015）4月17日董秘有最新回复
股市必读：百洋医药（301015）4月16日董秘有最新回复
证券之星 · 04-17
股市必读：百洋医药（301015）4月16日董秘有最新回复
百洋医药：公司合作药品锝[99mTc]佩昔瑞特加肽注射液无需参与国家集采即可进院销售
证券之星 · 04-16
百洋医药：公司合作药品锝[99mTc]佩昔瑞特加肽注射液无需参与国家集采即可进院销售
股市必读：百洋医药（301015）4月3日董秘有最新回复
证券之星 · 04-07
股市必读：百洋医药（301015）4月3日董秘有最新回复
百洋医药最新公告：完成向小核酸药物公司思合基因投资
证券之星 · 04-02
百洋医药最新公告：完成向小核酸药物公司思合基因投资
4月2日百洋医药涨6.04%，益民创新优势混合A基金重仓该股
证券之星 · 04-02
4月2日百洋医药涨6.04%，益民创新优势混合A基金重仓该股
3月30日百洋医药涨5.45%，益民创新优势混合A基金重仓该股
证券之星 · 03-30
3月30日百洋医药涨5.45%，益民创新优势混合A基金重仓该股
3月26日百洋医药跌5.09%，益民创新优势混合A基金重仓该股
证券之星 · 03-26
3月26日百洋医药跌5.09%，益民创新优势混合A基金重仓该股
3月25日百洋医药涨10.33%，益民创新优势混合A基金重仓该股
证券之星 · 03-25
3月25日百洋医药涨10.33%，益民创新优势混合A基金重仓该股
百洋医药（301015）披露对外投资暨关联交易公告，3月20日股价下跌2.56%
证券之星 · 03-20
百洋医药（301015）披露对外投资暨关联交易公告，3月20日股价下跌2.56%
百洋医药最新公告：拟2700万元投资思合基因布局小核酸药物领域
证券之星 · 03-19
百洋医药最新公告：拟2700万元投资思合基因布局小核酸药物领域
加载更多
公司概况
公司名称：
青岛百洋医药股份有限公司
所属行业：
批发业
上市日期：
2021-06-30
主营业务：
青岛百洋医药股份有限公司核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营,公司深度布局创新药与创新医疗器械，聚焦骨健康、抗器官纤维化、肿瘤脑转移、心血管等前沿领域，通过投资、研发转化与产业化平台运营，构建从源头创新到临床落地的全链条产业生态。公司的主要产品是药品、医疗器械、品牌服务。
发行价格：
7.64
{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋医药","latestPrice":23.81,"timestamp":1778569401000,"preClose":24.35,"halted":0,"volume":6188281,"delay":0,"changeRate":-0.0222,"floatShares":526000000,"shares":526000000,"eps":0.9772,"marketStatus":"已收盘","change":-0.54,"latestTime":"05-12 15:00:00","open":24.46,"high":24.47,"low":23.77,"amount":148000000,"amplitude":0.0287,"askPrice":23.82,"askSize":2,"bidPrice":23.81,"bidSize":444,"shortable":0,"etf":0,"ttmEps":0.9772,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":5,"adr":0,"adjPreClose":24.35,"symbolType":"stock","openAndCloseTimeList":[[1778549400000,1778556600000],[1778562000000,1778569200000]],"highLimit":26.79,"lowLimit":21.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525624077,"isCdr":false,"pbRate":5.14,"roa":"--","peRate":24.365534,"roe":"5.11%","epsLYR":0.9,"committee":0.833962,"marketValue":12515000000,"turnoverRate":0.0118,"status":1,"floatMarketCap":12514000000},"requestUrl":"/m/hq/s/301015","defaultTab":"news","newsList":[{"id":"2631688132","title":"百洋医药：公司持续丰富运营产品矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2631688132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631688132?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:36","pubTimestamp":1777534574,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：在年报中，未发现海露，海露已经不再代理了吗？百洋医药回复：投资者您好，公司持续丰富运营产品矩阵，并致力于推进优质医药健康产品快速进入临床应用。公司运营品种请以公司公告为准，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000047162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631157856","title":"百洋医药（301015）2026年一季报简析：净利润同比增长45.79%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631157856","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631157856?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:48","pubTimestamp":1777502893,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百洋医药发布2026年一季报。截至本报告期末，公司营业总收入17.84亿元，同比下降3.1%，归母净利润1.24亿元，同比上升45.79%。本报告期百洋医药盈利能力上升，毛利率同比增幅10.22%，净利率同比增幅46.29%。去年的净利率为7.62%，算上全部成本后，公司产品或服务的附加值一般。持有百洋医药最多的基金为益民创新优势混合A，目前规模为3.51亿元，最新净值1.4318，较上一交易日上涨1.5%，近一年上涨16.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631560248","title":"4月29日百洋医药涨5.01%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631560248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631560248?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:39","pubTimestamp":1777451982,"startTime":"0","endTime":"0","summary":"证券之星消息，4月29日百洋医药涨5.01%，收盘报25.34元，换手率2.25%，成交量11.82万手，成交额2.97亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。益民创新优势混合A目前规模为3.51亿元，最新净值1.4106，较上一交易日下跌0.78%，近一年上涨16.67%。张婷在任的基金产品包括:益民优势安享混合A，管理时间为2024年5月28日至今，期间收益率为52.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900052361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537129","title":"上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537129","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631537129?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:04","pubTimestamp":1777417480,"startTime":"0","endTime":"0","summary":"丨2026年4月29日星期三丨NO.1泰格医药一季度净利润同比减少70.36%4月28日，泰格医药发布2026年一季报，公司实现营业收入18.01亿元，同比增加15.17%；实现归属于上市公司股东的净利润4904.31万元，同比减少70.36%；实现归属于上市公司股东的扣除非经常性损益的净利润1.20亿元，同比增加17.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293723254882.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293723254882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","BMY","159938","09939","301015","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631587646","title":"图解百洋医药年报：第四季度单季净利润同比下降103.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631587646","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631587646?lang=zh_cn&edition=full","pubTime":"2026-04-29 02:08","pubTimestamp":1777399682,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药2025年年报显示，当年度公司主营收入75.07亿元，同比下降7.26%；归母净利润4.75亿元，同比下降31.36%；扣非净利润3.96亿元，同比下降39.59%；其中2025年第四季度，公司单季度主营收入18.79亿元，同比下降3.65%；单季度归母净利润-174.39万元，同比下降103.45%；单季度扣非净利润-1345.45万元，同比下降129.48%；负债率66.2%，投资收益1959.74万元，财务费用1.08亿元，毛利率37.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900005976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630363187","title":"百洋医药：公司运营品牌安博美的销售按经营计划有序开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2630363187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630363187?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:48","pubTimestamp":1777276089,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月27日在投资者关系平台上答复投资者关心的问题。投资者提问：按照协议，安博美今年6月份需要销售450万瓶，能不能按期完成？百洋医药回复：投资者您好，公司运营品牌安博美的销售按经营计划有序开展，销售收入请以公司公告为准，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700024407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630631283","title":"百洋医药：ZAP-X已完成在北京大学国际医院、北京天坛普华医院的落地部署","url":"https://stock-news.laohu8.com/highlight/detail?id=2630631283","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630631283?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:48","pubTimestamp":1777276085,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月27日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问zap-x放射设备国内已装机几台？是否已开展诊疗工作？百洋医药回复：投资者您好，公司ZAP-X已完成在北京大学国际医院、北京天坛普华医院的落地部署，诊疗工作按经营计划推进中，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700024395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630836319","title":"百洋医药：公司目前无自建核药药房的经营计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2630836319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630836319?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:48","pubTimestamp":1777276084,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司的核药药房是自建还是租赁合作？自建多少个，合作多少个？百洋医药回复：投资者您好，公司目前无自建核药药房的经营计划，后续合作情况请关注公司公告，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700024392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628743287","title":"百洋医药：核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2628743287","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628743287?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:51","pubTimestamp":1776675068,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药04月20日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000022337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628079349","title":"股市必读：百洋医药（301015）4月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2628079349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628079349?lang=zh_cn&edition=full","pubTime":"2026-04-20 03:00","pubTimestamp":1776625233,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百洋医药报收于26.53元，上涨1.18%，换手率2.61%，成交量13.72万手，成交额3.63亿元。董秘最新回复投资者： 2026年的医保谈判已经结束，核药作为创新药，今年还有机会进医保吗？当日关注点来自交易信息汇总：4月17日主力资金净流入1385.57万元，显示主力对个股短期关注度提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000001089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628924852","title":"股市必读：百洋医药（301015）4月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2628924852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628924852?lang=zh_cn&edition=full","pubTime":"2026-04-17 01:45","pubTimestamp":1776361511,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘，百洋医药报收于26.22元，上涨1.31%，换手率2.96%，成交量15.57万手，成交额4.06亿元。董秘最新回复投资者： 董秘您好，公司合作药品锝[99mTc]佩昔瑞特加肽注射液需要通过集采才能进入医院销售吗？当日关注点来自交易信息汇总：4月16日主力资金净流出1424.12万元，散户资金净流入1375.91万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700002916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627264091","title":"百洋医药：公司合作药品锝[99mTc]佩昔瑞特加肽注射液无需参与国家集采即可进院销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2627264091","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627264091?lang=zh_cn&edition=full","pubTime":"2026-04-16 15:00","pubTimestamp":1776322846,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司合作药品锝[99mTc]佩昔瑞特加肽注射液需要通过集采才能进入医院销售吗？百洋医药回复：投资者您好，公司合作药品锝 [99mTc] 佩昔瑞特加肽注射液无需参与国家集采即可进院销售，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600021360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625012609","title":"股市必读：百洋医药（301015）4月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2625012609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625012609?lang=zh_cn&edition=full","pubTime":"2026-04-07 04:02","pubTimestamp":1775505738,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，百洋医药报收于25.96元，下跌0.15%，换手率6.25%，成交量32.85万手，成交额8.89亿元。董秘最新回复投资者： 请问公司在北京门头沟有生产基地或子公司吗？交易信息汇总资金流向4月3日主力资金净流入224.96万元，占总成交额0.25%；游资资金净流入555.46万元，占总成交额0.62%；散户资金净流出780.42万元，占总成交额0.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624742125","title":"百洋医药最新公告：完成向小核酸药物公司思合基因投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2624742125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624742125?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:01","pubTimestamp":1775120506,"startTime":"0","endTime":"0","summary":"百洋医药(301015.SZ)公告称，公司对外投资暨关联交易事项取得进展。为拓展小核酸药物领域布局，公司与思合基因(北京)生物科技有限公司等相关方签署《投资协议》，约定以现金方式向思合基因投资2700万元，投资后持有其10%股权。截至本公告披露日，公司已与各方签署协议并足额支付投资款，本次交易已完成交割。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200028250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624713345","title":"4月2日百洋医药涨6.04%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624713345","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624713345?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:15","pubTimestamp":1775117706,"startTime":"0","endTime":"0","summary":"证券之星消息，4月2日百洋医药涨6.04%创60日新高，收盘报26.0元，换手率4.49%，成交量23.62万手，成交额6.08亿元。重仓百洋医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。益民创新优势混合A目前规模为4.04亿元，最新净值1.3376，较上一交易日上涨1.45%，近一年上涨9.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200026221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623739089","title":"3月30日百洋医药涨5.45%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623739089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623739089?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:29","pubTimestamp":1774859375,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日百洋医药涨5.45%，收盘报23.78元，换手率2.21%，成交量11.63万手，成交额2.74亿元。重仓百洋医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。益民创新优势混合A目前规模为4.04亿元，最新净值1.3252，较上一交易日上涨1.06%，近一年上涨8.52%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837189","title":"3月26日百洋医药跌5.09%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837189","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622837189?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:28","pubTimestamp":1774513686,"startTime":"0","endTime":"0","summary":"证券之星消息，3月26日百洋医药跌5.09%，收盘报21.99元，换手率1.69%，成交量8.87万手，成交额1.97亿元。重仓百洋医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。益民创新优势混合A目前规模为4.04亿元，最新净值1.3205，较上一交易日上涨1.27%，近一年上涨8.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600029073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622025183","title":"3月25日百洋医药涨10.33%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622025183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622025183?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:27","pubTimestamp":1774427266,"startTime":"0","endTime":"0","summary":"证券之星消息，3月25日百洋医药涨10.33%，收盘报23.17元，换手率1.44%，成交量7.57万手，成交额1.67亿元。重仓百洋医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。益民创新优势混合A目前规模为4.04亿元，最新净值1.3039，较上一交易日上涨1.85%，近一年上涨7.01%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500030709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620784595","title":"百洋医药（301015）披露对外投资暨关联交易公告，3月20日股价下跌2.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620784595","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620784595?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:30","pubTimestamp":1773999034,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，百洋医药报收于21.3元，较前一交易日下跌2.56%，最新总市值为111.96亿元。该股当日开盘21.9元，最高22.15元，最低21.3元，成交额达5985.52万元，换手率为0.53%。近日，百洋医药发布《关于对外投资暨关联交易的公告》。公司拟以现金2,700万元向思合基因（北京）生物科技有限公司投资，获得其10%股权。本次交易构成与专业投资机构共同投资的关联交易，因门头沟百洋基金为公司关联人。公司已召开董事会审议通过，无需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000030573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620241235","title":"百洋医药最新公告：拟2700万元投资思合基因布局小核酸药物领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2620241235","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620241235?lang=zh_cn&edition=full","pubTime":"2026-03-19 18:51","pubTimestamp":1773917467,"startTime":"0","endTime":"0","summary":"百洋医药公告称，为拓展公司在小核酸药物领域的布局，公司拟以现金2700万元向思合基因(北京)生物科技有限公司增资，取得其10%股权。本次交易构成与关联方北京市门头沟区百洋医药产业投资基金共同投资的关联交易，因该基金由公司控股股东控制。本次投资不导致公司合并报表范围变更，亦不构成重大资产重组。交易定价以评估值为基础，思合基因投前估值2.38亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900031896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778592460691,"stockEarnings":[{"period":"1week","weight":-0.0122},{"period":"1month","weight":0.0227},{"period":"3month","weight":0.0188},{"period":"6month","weight":-0.0053},{"period":"1year","weight":0.3997},{"period":"ytd","weight":0.0318}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0599},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.2642},{"period":"ytd","weight":0.0645}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"青岛百洋医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"14963人(较上一季度增加8.92%)","perCapita":"35123股","listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","registeredCapital":"52562万元","survey":" 青岛百洋医药股份有限公司核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营,公司深度布局创新药与创新医疗器械，聚焦骨健康、抗器官纤维化、肿瘤脑转移、心血管等前沿领域，通过投资、研发转化与产业化平台运营，构建从源头创新到临床落地的全链条产业生态。公司的主要产品是药品、医疗器械、品牌服务。","listedPrice":7.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋医药,301015,百洋医药股票,百洋医药股票老虎,百洋医药股票老虎国际,百洋医药行情,百洋医药股票行情,百洋医药股价,百洋医药股市,百洋医药股票价格,百洋医药股票交易,百洋医药股票购买,百洋医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}